Hims & Hers Health (NYSE:HIMS) CFO Sells $79,420.50 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 3,975 shares of the firm’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $19.98, for a total value of $79,420.50. Following the completion of the transaction, the chief financial officer directly owned 318,789 shares of the company’s stock, valued at $6,369,404.22. The trade was a 1.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Friday, March 20th, Oluyemi Okupe sold 9,217 shares of Hims & Hers Health stock. The stock was sold at an average price of $23.77, for a total value of $219,088.09.
• On Tuesday, January 20th, Oluyemi Okupe sold 9,067 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.34, for a total value of $275,092.78.

Hims & Hers Health Price Performance

NYSE HIMS traded down $0.79 during trading hours on Tuesday, reaching $19.54. 20,834,213 shares of the stock traded hands, compared to its average volume of 33,518,930. The stock has a 50 day simple moving average of $20.47 and a two-hundred day simple moving average of $34.29. Hims & Hers Health, Inc. has a 1 year low of $13.74 and a 1 year high of $70.43. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70. The company has a market cap of $4.45 billion, a price-to-earnings ratio of 38.31, a price-to-earnings-growth ratio of 2.31 and a beta of 2.32.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, February 23rd. The company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.02 by $0.06. The firm had revenue of $617.82 million for the quarter, compared to the consensus estimate of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The company’s quarterly revenue was up 28.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.11 earnings per share. On average, analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have weighed in on HIMS shares. BTIG Research cut Hims & Hers Health from a “buy” rating to a “neutral” rating in a research report on Tuesday, February 24th. Leerink Partners boosted their price objective on shares of Hims & Hers Health from $17.50 to $25.00 and gave the stock a “market perform” rating in a report on Monday, March 16th. Barclays boosted their target price on shares of Hims & Hers Health from $25.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, March 11th. Citigroup upgraded shares of Hims & Hers Health from a “sell” rating to a “neutral” rating and boosted their target price for the company from $13.25 to $24.00 in a research note on Tuesday, March 10th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research note on Friday, March 27th. Three equities research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $31.71.

Institutional Investors Weigh In On Hims & Hers Health

Hedge funds have recently modified their holdings of the business. Quent Capital LLC bought a new position in Hims & Hers Health in the 3rd quarter worth $28,000. Flagship Harbor Advisors LLC bought a new position in Hims & Hers Health in the 4th quarter worth $28,000. Binnacle Investments Inc bought a new position in Hims & Hers Health in the 3rd quarter worth $28,000. Bogart Wealth LLC boosted its holdings in Hims & Hers Health by 235.8% in the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock worth $29,000 after buying an additional 632 shares during the period. Finally, Geneos Wealth Management Inc. bought a new position in Hims & Hers Health in the 1st quarter worth $30,000. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.